INTRODUCTION
Autoimmune hepatitis (AIH) is a distinct group of acute and chronic necro-inflammatory disorder. Liverrelated autoantibodies are crucial for the correct diagnosis and classification of autoimmune liver diseases (AILD), namely AIH types 1 and 2 (AIH-1 and 2), primary biliary cirrhosis (PBC), and the sclerosing cholangitis variants in adults and children. AIH-1 is specified by anti-nuclear antibody (ANA) and smooth muscle antibody (SMA). AIH-2 is specified by antibody to liver kidney microsomal antigen type-1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1). SMA, ANA and anti-LKM antibodies can be present in de-novo AIH following liver transplantation. PBC is specified by antimitochondrial antibodies (AMA) reacting with enzymes of the 2-oxo-acid dehydrogenase complexes (chiefly pyruvate dehydrogenase complex E2 subunit) [1] .Several studies clearly demonstrate that liver cell damage in autoimmune hepatitis (AIH) is mediated by autoimmune reaction against normal constituents of the hepatocytes [2] .The presence of circulating autoantibodies is the single most significant finding in AIH, the discovery of auto-antibodies directed against different cellular targets, including endoplasmic reticulum membrane proteins, nuclear antigens and cytosolic antigen has led to a suggested sub-classification of AIH based upon the presence of three specific autoantibody profiles [3] . In Egypt, where hepatitis C infection is the commonest liver disease among Egyptian patients, the other liver disorder like AILD are usually under studied and it's role in causation of chronic liver disease among Egyptians are not well studied and the true prevalence of autoimmune liver disorder in Egypt is not well know. 
PATIENTS AND METHODS

RESULTS
Fifty Egyptian patients with non-B non-C chronic hepatitis were selected out of 795 chronic hepatitis patients. The mean age of this patients was 39.72 + 12.12 years, range (15-60 years). They were 32 female (64%) and 18 male (36%). As a regard for laboratory findings all patients (100%) had elevated ALT (>41 u/L) and AST (>38 u/L) levels but 36 patients (72%) of them had elevated ALT more than 3 folds and 42 patients (84%) of them had elevated AST more than 3 folds. Total bilirubin was elevated more than 2 mg/dl in 44 patients (88%), direct bilirubin increased in 42 patients (84%). Hypoalbuminemia (<3.4 g/dl) was detected in 18 patients (36%), 2 cases of them were associated with albuminuria. Hypergammaglobulinaemia (γ-globuline >1.5 g/dl) was detected in 36 patients (72%), also prothrombin time was prolonged (>14 sec) in 28 patients (56%). As a regard for histopathological findings by liver biopsy; all the studied patients (100%) showed inflammatory reactions with chronic inflammatory cells predominate in portal tracts mostly of lymphocyte in 42 patients (84%), followed by plasma cells in 24 patients (48%) and finally P.N.Ls in 12 patients (24%). Piecemeal necrosis (interface hepatitis) was reported in 32 patients (64%), fibrosis was recorded in 36 patients (72%). As regard the liver parenchyma, disturbed architecture was seen in 12 patients (24%), hyperplastic kuppfer cells in 14 patients (28%), and cirrhotic nodules in 10 patients (20%). The liver cells showed different pathological changes, as ballooning in 16 patients (32%), moderate to marked steatosis in 14 patients (28%), hydropic changes and ground glass appearance in 4 patients (8%). On the other hand, findings suggestive cholestasis, bile duct proliferation and ductopenia were encountered among 18 patients (36%), 10 patients (20%) and 10 patients (20%) respectively) ( Table 1 & Figs. 1,2,3). The auto-antibodies studied in our group of patients showed that 24 patients (48%) had ANA with statistically significant difference (P=0.004) regarding other auto-antibodies. Also, 22 patients (44%) had ASM auto-antibodies, 14 patients (63.4%) of them showed titer 1/40 with high statistically significant difference (P<0.001). As regard ALKM-1 auto-antibodies, it was reported in 12 patients (24%), 6 patients (50%) of them showed titer 1/40 with high statistically significant difference (P<0.001). On the other hand, 10 patients (20%) had AMA at titer 1/20 with high statistically significant difference (P<0.001) when compared with other auto-antibodies ( Table 2) . As a regard for the suspected etiological diagnosis, 16 patients (32%) out of 50 patients were diagnosed as AIH, most of them (10 patients "20%") was of type I. While type II AIH were diagnosed in 2 patients (4%) only, while 4 patients (8%) with unclassified AIH were also reported, and 16 patients (32%) were diagnosed as overlap syndrome. On the other hand, other chronic liver disorders such as Wilson's disease and glycogen storage disease were the least reported suspected diagnosis as each of them was encountered among 2 patients (4%). Also 8 patients (16%) were diagnosed as a cases of cryptogenic chronic hepatitis and 6 patients (12%) were diagnosed as non-alcoholic steato-hepatitis (NASH) ( Table 3) . AMA positive overlap syndrome was more common in patients with age group 20-40 years (8 out of 22 patients) (36.4%). While only 4 out of 14 patients (28.6%) were less than 20 years had overlap syndrome with AMA negative. All patients with NASH were of age group 20-40 years. Also ANA and ALKM-1 were more common in the same age group; 12 patients (50%) and 8 patients (66.7%) respectively. Ten female patients out of 32 (31.25%) had AIH type I which is of statistically significant difference (P=0.02). On the other hand, 6 male patients out of 18 (33.3%) had cryptogenic chronic hepatitis with statistically significant difference (P= 0.035). A part from these difference, there was no statistically significant difference between sex distribution and diagnosis. Auto-antibodies are more common in female than in male patients. All patients with AMA positive overlap syndrome had hyperbilirubinemia and increased alkaline phosphatase more than 3 folds that consistent with cholestatic pattern with statistically significant difference (P=0.01). There is no statistically significant difference between the studied auto-antibodies and the level of serum bilirubin, serum albumin, gamma globulin, transaminase, alkaline phosphatase or prothrombin time and I.N.R (Table 4 ). There was high statistically significant difference in the differentiation of the cells in portal tract among our group of patients (P<0.001). All patients with overlap syndrome with AMA positive had cholestasis with high statistically significant difference (P<0.001). Eight patients (80%) of them had ductopenia with high statistically significant difference (P<0.001). On the other hand, bile duct proliferation was reported among 4 patients out of 6 with overlap syndrome with AMA negative with statistically significant difference (P=0.004). Twenty patients (90.9%) of the patients who were positive for ASM autoantibody had lymphocytes in portal tracts (P=0.02). However, 6 (50%) of ALKM-1 positive cases had P.N.Ls in liver biopsy with statistically significant difference (P=0.02). As regard bile ducts and cholestatic features, all patients with AMA positive showed features of cholestasis (Figs. 1,2,3,4) . Both types of AIH have similar course and outcome. In contrast to the unclassified type of AIH which had more advanced clinical manifestation, as 50% of them had shrunken liver and 50% had history of hematemesis and melena. Detection of AMA in AIH might identify a subset of patients at risk of developing hepatitic/cholestatic syndrome. 
DISCUSSION
AIH has been defined as "an unresolving, predominantly periportal hepatitis, usually with hypergammaglobulinemia and tissue autoantibodies, which is responsive to immunosuppressive therapy in most cases." It is a relatively rare disorder, with a preponderance of female patients, that can present at any age (although onset in most cases is after 40 years of age) [5] . It is one entity of the heterogeneous syndrome of chronic hepatitis, the true prevalence of AIH among the countries in the world are not well known, especially in countries in which viral hepatitis B and C are endemic, and the presence of circulating auto-antibodies is the single most significant finding in AIH and they are the key for diagnosis [6] . In the present study, measurement of auto antibodies in the sera of AILD patients revealed that 24 patients (48%) were positive for ANA, 22 patients (44%) were positive for ASMA, 12 patients (24%) were positive for LKM-1 antibody and 10 patients (20%) were positive for AMA. This measurements reflected the significant serum levels of autoantibodies. This result is in contrast with the study which was carried out in upper Egypt by ElSayed et al. [7] who found that LKM-1 autoantibody was the most common autoantibody detected in patients serum (62.5%). This discrepancy is due to the difference in selective criteria, as they studied serum autoantibodies with inclusion of HCV, HBV and AILD in studied patients. Classification of patients in the present study according to the etiological diagnosis revealed that, out of the Egyptian 50 patients with non-B, non-C chronic hepatitis 32 (64%) were diagnosed as AILDs, 16 patients (32%) of them were diagnosed as AIH, most of them; 10 patients (62.5%) were classified as type I AIH, with positive ANA and/or ASMA, 2 patients (12.5%) were classified as type 2 AIH, with positive ALKM-1, but 4 patients (25%) could not been classified on the bases of available autoantibodies profiles. Overlap syndrome (hepatitis and cholestatic AILD) with or without AMA was diagnosed in 16 patients (32%), 10 patients of them (62.5%) had AMA positive and 6 patients (37.5%) were AMA negative. So, the prevalence of AILDs in our area was about 40.2/100000, half of them were of AIH, mostly of AIH type I and the other half was of overlap syndrome mostly with AMA positive sera. In comparison with prevalence of AILDs among various countries in the world, it was 1.9/100.000 in North America [8] , 16.9/100.000 in Europe [9] , 14/100.000, 5.6%, 2% in India [10] . Most AIH type I patients were of age around forty years, and patients with unclassified AIH were in peri-pubertally 50% and another 50% were between the fourth and sixth decades. This finding is in concordance with other study [11] , they reported that AIH is disease of young especially women. On the other hand, Mc Farlane [5] reported that most cases of AIH reported in two peaks of onset: peripubertally and between fourth and sixth decades of life. However the point of controversy is the age of AIH type II patients, which is predominantly affects the children [11, 12] , while in the present study, patients were adults, this in agreement with Czaja et al. [13] . In the present study, biochemical liver tests (LFT) typically showed a "hepatitic" (with or without cholestatic) pattern of abnormalities, as serum aminotransferase activity and bilirubin concentrations varied widely from very mildly abnormal to more than 50 fold rise the upper normal limits in all patients with AILDs and cryptogenic chronic hepatitis, but the hyperbilirubinemia is notably cholestatic in all patients (100%) with overlap syndromes, as it was associated with alkaline phosphatase elevation more than 3 time the upper normal limit. This observation is in coincidence with many other studies [14, 15, 16] , they classified overlap syndrome as an "intermediate level between cholestatic form of AIH or hepatic form of cholestatic syndromes". The hypergammaglobulinemia, which is the most reliable laboratory parameter in AILDs, was increased in this study in all patients with AILDs and much higher value were observed in type I AIH with average 2.5 g/dl, when compared to other types of AILDs, this observation also recorded by Porta and Squires [16, 17] . There was no statistically significant difference between the degree of liver function impairement and the presence of specific auto-antibody, indicating that these auto-antibodies should be used for diagnostic purpose only and they do not correlate with disease severity and activity and also similar to that as reported by Luxon [18] . In the present study, histopatho-logical examination of AIH group showed that, interface hepatitis was the main feature, the inflammatory activity within and around the portal tracts predominated over the lobular changes with aggregation of lymphocytes, plasma cells and polymorphonuclear cells in the portal tract or periportal area. This periportal inflammatory cell infiltration present without bile duct damage. This was coincides with that of other study [19] . As regard overlap syndrome, mixed cholestatic and hepatocellular features were found in them which supported the clinical diagnosis of overlap syndrome. The histologic features in overlap group comprised of cholestasis in 100% of patients, ductopenia in 10 patients (62.5%), proliferation of bile ducts in 6 patients (37.5%) and peripheral xanthomatous changes and pseudoglandular pattern in 2 patients (12.5%) which coincidence with others [19, 20] . In the present study, measurement of numbers and titres of each autoantibody in each group of studied patients revealed that, although ANA was found in large number of patients with overlap syndrome (AMA positive and AMA negative) in 10 patients (100%) and 4 patients (66.7%) respectively, it was detected in low titre (1/20) in all of them, compared to its presence in high titre in patients with AIH especially in AIH type I. ALKM-1 was detected in high titre in 100% of patients with AIH type 2 (1/80), also it was found in AMA positive patients and it was not present in AMA negative patients. However, AMA reactivity may be false because of confusion with ALKM-1 by indirect immuno-fluorescence as proposed [21] . In this work, distribution of auto-antibodies among each group of studied patients arised question about 4 patients who cannot be classified according to auto-antibody profiles, as 2 of these patients had (ANA, ASM and LKM-1) and the other two had (ASM and LKM-1). Also, among 6 AMA positive overlap syndrome patients, 4 of them had 4 autoantibodies (ANA, ASM, LKM-1 and AMA) and the other 2 patients showed 3 autoanti-bodies (ANA, LKM-1 and AMA). So, although the autoantibodies serve mainly as a marker of disease and key for diagnosis, but there is still a long way to go, as many authors considering the problems with definition of AIH and relation to stage of disease, overlap and/or coexistence among autoimmune diseases, and distinction of possible subtypes, suggested the necessity of further characterization of autoantibodies relevant for AIH and a better pathophysiological understanding will allow subclassification on the basis of etiopathogenesis [22] . So, as the classification of patients according to auto-antibody profiles and/or different immuno-genetic markers is a controversial area with some authorities recommending various subdivisions of AIH along these lines [23, 24] . So characterization of other auto-antibodies in the future rather than the conventional auto-antibodies may facilitate reclassification of patients from cryptogenic chronic hepatitis to AIH.
